UTHR [NASD]
United Therapeutics Corporation
Index- P/E15.16 EPS (ttm)14.44 Insider Own0.10% Shs Outstand45.20M Perf Week14.64%
Market Cap9.81B Forward P/E11.47 EPS next Y19.09 Insider Trans-66.11% Shs Float44.42M Perf Month17.56%
Income687.40M PEG7.98 EPS next Q4.04 Inst Own99.60% Short Float2.52% Perf Quarter13.38%
Sales1.77B P/S5.55 EPS this Y-12.90% Inst Trans2.36% Short Ratio2.35 Perf Half Y10.07%
Book/sh92.40 P/B2.37 EPS next Y9.80% ROA13.50% Target Price227.62 Perf Year18.18%
Cash/sh50.61 P/C4.33 EPS next 5Y1.90% ROE17.60% 52W Range158.38 - 218.38 Perf YTD1.33%
Dividend- P/FCF14.57 EPS past 5Y-8.00% ROI9.20% 52W High0.26% Beta0.60
Dividend %- Quick Ratio8.50 Sales past 5Y1.10% Gross Margin92.90% 52W Low38.24% ATR8.15
Employees965 Current Ratio8.80 Sales Q/Q21.80% Oper. Margin51.20% RSI (14)76.48 Volatility5.97% 4.29%
OptionableYes Debt/Eq0.19 EPS Q/Q724.60% Profit Margin38.90% Rel Volume2.05 Prev Close210.14
ShortableYes LT Debt/Eq0.19 EarningsMay 04 BMO Payout0.00% Avg Volume475.23K Price218.95
Recom1.80 SMA2019.18% SMA5019.32% SMA20012.89% Volume996,060 Change4.19%
Feb-11-22Initiated BTIG Research Neutral
Jul-14-21Upgrade Argus Hold → Buy $205
Apr-26-21Resumed Credit Suisse Outperform $196
Feb-01-21Upgrade H.C. Wainwright Neutral → Buy $125 → $195
Sep-14-20Resumed JP Morgan Overweight $142
Jun-25-20Reiterated H.C. Wainwright Neutral $85 → $125
Mar-10-20Upgrade Jefferies Hold → Buy $123
Feb-27-20Upgrade Cowen Market Perform → Outperform $119 → $145
Jan-31-20Upgrade JP Morgan Neutral → Overweight $120
Dec-03-19Initiated BofA/Merrill Underperform
Aug-01-19Upgrade Ladenburg Thalmann Neutral → Buy $103 → $106
Aug-01-19Upgrade Jefferies Underperform → Hold $90
Jul-01-19Upgrade Credit Suisse Neutral → Outperform $98 → $101
May-17-19Upgrade UBS Sell → Neutral $115 → $94
May-09-19Upgrade Credit Suisse Underperform → Neutral $98
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
May-24-22 03:02PM  
02:04PM  
01:48PM  
09:40AM  
06:00AM  
May-11-22 06:35AM  
May-10-22 02:26PM  
May-05-22 11:12AM  
May-04-22 02:38PM  
07:15AM  
06:00AM  
Apr-29-22 06:00AM  
Apr-27-22 03:03PM  
06:00AM  
Apr-13-22 03:04PM  
Apr-06-22 06:00AM  
Mar-14-22 02:56PM  
05:18AM  
Mar-10-22 08:26AM  
Mar-08-22 06:00AM  
Mar-01-22 06:00AM  
Feb-25-22 11:09AM  
10:45AM  
10:00AM  
12:30AM  
Feb-24-22 07:15AM  
06:00AM  
Feb-21-22 09:30AM  
06:00AM  
Feb-17-22 03:21PM  
Feb-16-22 10:58AM  
09:54AM  
Feb-15-22 05:03PM  
Feb-07-22 06:38PM  
Feb-04-22 09:38AM  
Feb-03-22 05:38PM  
02:36PM  
Jan-21-22 06:00AM  
Jan-19-22 09:38PM  
Jan-06-22 11:24AM  
07:56AM  
Jan-03-22 12:43PM  
Dec-30-21 07:25AM  
06:00AM  
Dec-28-21 02:38AM  
Dec-27-21 05:25PM  
Dec-23-21 10:15AM  
Dec-21-21 06:15PM  
Dec-19-21 05:38AM  
Dec-17-21 09:15PM  
Dec-14-21 02:57PM  
Dec-07-21 09:21PM  
Dec-04-21 02:29PM  
Dec-03-21 11:31AM  
06:00AM  
Nov-26-21 06:00AM  
Nov-22-21 10:39AM  
Nov-10-21 02:59PM  
Nov-08-21 10:28AM  
Nov-07-21 12:57PM  
Nov-04-21 09:10AM  
Nov-03-21 12:01PM  
07:15AM  
06:00AM  
Nov-01-21 06:00AM  
Oct-27-21 04:25PM  
06:00AM  
Oct-24-21 05:09AM  
Oct-21-21 06:08AM  
06:00AM  
Oct-20-21 03:03PM  
07:00AM  
01:28AM  
Oct-19-21 11:18PM  
10:29AM  
Oct-18-21 02:38PM  
11:42AM  
09:20AM  
08:45AM  
06:36AM  
06:02AM  
06:00AM  
Oct-15-21 08:49AM  
Oct-11-21 06:00AM  
Oct-05-21 01:53PM  
Oct-04-21 01:44PM  
Oct-01-21 01:49PM  
Sep-30-21 04:30PM  
Sep-10-21 06:00AM  
Sep-07-21 09:54AM  
06:00AM  
Sep-03-21 11:31AM  
Aug-25-21 06:00AM  
Aug-24-21 06:00AM  
Aug-12-21 11:30AM  
Aug-05-21 10:09AM  
Aug-04-21 05:56PM  
12:30PM  
07:15AM  
06:00AM  
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHON PAUL AEVP & GENERAL COUNSELMay 19Option Exercise111.006,000666,00042,397May 20 04:32 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 19Sale183.436,0001,100,59336,397May 20 04:32 PM
PATUSKY CHRISTOPHERDirectorMay 17Option Exercise63.902,000127,8003,680May 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 05Option Exercise111.006,000666,00042,397May 06 04:30 PM
DWEK RAYMONDDirectorMay 05Option Exercise48.112,00096,2202,000May 06 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 05Sale190.656,0001,143,89436,397May 06 04:30 PM
DWEK RAYMONDDirectorApr 28Option Exercise48.112,00096,2202,000Apr 29 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 21Option Exercise111.006,000666,00042,487Apr 22 04:30 PM
DWEK RAYMONDDirectorApr 21Option Exercise48.112,00096,2202,000Apr 22 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 21Sale189.186,0001,135,07836,397Apr 22 04:30 PM
DWEK RAYMONDDirectorApr 14Option Exercise48.112,00096,2202,000Apr 15 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 07Option Exercise111.006,000666,00042,487Apr 08 04:30 PM
PATUSKY CHRISTOPHERDirectorApr 07Option Exercise63.902,000127,8003,680Apr 08 04:30 PM
DWEK RAYMONDDirectorApr 07Option Exercise48.112,00096,2202,000Apr 08 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 07Sale185.526,0001,113,09536,487Apr 08 04:30 PM
Thompson Tommy GDirectorMar 29Option Exercise48.111,50072,1658,020Mar 30 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 17Option Exercise111.006,000666,00042,487Mar 18 04:30 PM
Thompson Tommy GDirectorMar 17Option Exercise48.111,50972,5988,029Mar 18 04:36 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 17Sale182.426,0001,094,50136,487Mar 18 04:30 PM
Thompson Tommy GDirectorMar 16Option Exercise48.111,50072,1658,020Mar 18 04:36 PM
Thompson Tommy GDirectorMar 15Option Exercise48.111,50072,1658,020Mar 16 04:35 PM
PATUSKY CHRISTOPHERDirectorMar 15Option Exercise88.032,000176,0603,680Mar 16 04:35 PM
Thompson Tommy GDirectorMar 10Option Exercise48.111,00048,1107,520Mar 11 04:35 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 03Option Exercise111.006,000666,00042,369Mar 04 04:35 PM
Thompson Tommy GDirectorMar 03Option Exercise48.111,50072,1658,020Mar 04 04:33 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 03Sale174.126,0001,044,71536,369Mar 04 04:35 PM
MAHON PAUL AEVP & GENERAL COUNSELFeb 17Option Exercise111.006,000666,00036,369Feb 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELFeb 17Sale202.176,0001,213,02430,369Feb 18 04:30 PM
MAHON PAUL AEVP & General CounselFeb 03Option Exercise111.006,000666,00036,369Feb 04 04:30 PM
MAHON PAUL AEVP & General CounselFeb 03Sale200.106,0001,200,61630,369Feb 04 04:30 PM
MAHON PAUL AEVP & General CounselJan 20Option Exercise111.006,000666,00036,369Jan 21 04:31 PM
MAHON PAUL AEVP & General CounselJan 20Sale205.576,0001,233,44030,369Jan 21 04:31 PM
MAHON PAUL AEVP & General CounselJan 06Sale192.466,0001,154,78730,369Jan 06 05:08 PM
ROTHBLATT MARTINE AChairperson & CEODec 29Option Exercise53.423,082164,6403,212Dec 29 04:31 PM
ROTHBLATT MARTINE AChairperson & CEODec 29Sale212.493,082654,894130Dec 29 04:31 PM
ROTHBLATT MARTINE AChairperson & CEODec 27Option Exercise53.423,082164,6403,212Dec 27 04:48 PM
ROTHBLATT MARTINE AChairperson & CEODec 27Sale213.313,082657,421130Dec 27 04:48 PM
ROTHBLATT MARTINE AChairperson & CEODec 22Option Exercise53.423,082164,6403,212Dec 22 05:45 PM
ROTHBLATT MARTINE AChairperson & CEODec 22Sale202.443,082623,920130Dec 22 05:45 PM
BENKOWITZ MICHAELPresident and COODec 21Option Exercise61.062,400146,5444,635Dec 22 04:32 PM
ROTHBLATT MARTINE AChairperson & CEODec 20Option Exercise53.423,082164,6403,212Dec 21 04:47 PM
ROTHBLATT MARTINE AChairperson & CEODec 20Sale200.003,082616,400130Dec 21 04:47 PM
MAHON PAUL AEVP & General CounselDec 16Option Exercise111.006,000666,00042,369Dec 17 04:32 PM
BENKOWITZ MICHAELPresident and COODec 16Option Exercise61.064,000244,2406,235Dec 17 04:30 PM
MAHON PAUL AEVP & General CounselDec 16Sale195.536,0001,173,17136,369Dec 17 04:32 PM
BENKOWITZ MICHAELPresident and COODec 14Option Exercise61.064,000244,2406,235Dec 15 04:32 PM
BENKOWITZ MICHAELPresident and COODec 07Option Exercise61.064,000244,2406,235Dec 08 05:02 PM
MAHON PAUL AEVP & General CounselDec 02Option Exercise111.006,000666,00042,369Dec 02 04:30 PM
MAHON PAUL AEVP & General CounselDec 02Sale189.366,0001,136,14036,369Dec 02 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 24Option Exercise53.423,083164,6943,213Nov 29 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 24Sale200.643,083618,573130Nov 29 04:30 PM
BENKOWITZ MICHAELPresident and COONov 23Option Exercise61.064,000244,2406,235Nov 24 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 22Option Exercise53.423,083164,6943,213Nov 24 04:31 PM
ROTHBLATT MARTINE AChairperson & CEONov 22Sale200.423,083617,895130Nov 24 04:31 PM
MAHON PAUL AEVP & General CounselNov 18Option Exercise111.006,000666,00042,369Nov 18 04:47 PM
BENKOWITZ MICHAELPresident and COONov 18Option Exercise53.834,000215,3206,235Nov 19 04:57 PM
ROTHBLATT MARTINE AChairperson & CEONov 17Option Exercise53.423,083164,6943,213Nov 17 05:41 PM
ROTHBLATT MARTINE AChairperson & CEONov 17Sale201.903,083622,458130Nov 17 05:41 PM
BENKOWITZ MICHAELPresident and COONov 16Option Exercise53.834,000215,3206,235Nov 17 05:40 PM
ROTHBLATT MARTINE AChairman & CEONov 15Option Exercise53.423,083164,6943,213Nov 15 04:35 PM
ROTHBLATT MARTINE AChairman & CEONov 15Sale203.453,083627,236130Nov 15 04:35 PM
PATUSKY CHRISTOPHERDirectorNov 11Option Exercise63.902,000127,8003,680Nov 12 04:35 PM
BENKOWITZ MICHAELPresident and COONov 11Option Exercise53.834,000215,3206,235Nov 12 04:33 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise53.423,083164,6943,213Nov 10 04:33 PM
ROTHBLATT MARTINE AChairman & CEONov 10Sale200.003,083616,600130Nov 10 04:33 PM
BENKOWITZ MICHAELPresident and COONov 09Option Exercise53.834,000215,3206,235Nov 10 04:34 PM
ROTHBLATT MARTINE AChairman & CEONov 08Option Exercise53.423,083164,6943,213Nov 08 04:32 PM
DWEK RAYMONDDirectorNov 08Option Exercise48.113,000144,3303,000Nov 08 06:51 PM
ROTHBLATT MARTINE AChairman & CEONov 08Sale200.943,083619,498130Nov 08 04:32 PM
PATUSKY CHRISTOPHERDirectorNov 08Sale200.162,300460,3681,680Nov 08 04:30 PM
MAHON PAUL AEVP & General CounselNov 04Option Exercise111.006,000666,00042,369Nov 04 04:31 PM
ROTHBLATT MARTINE AChairman & CEONov 04Option Exercise53.423,083164,6943,213Nov 05 04:33 PM
BENKOWITZ MICHAELPresident and COONov 04Option Exercise53.834,000215,3206,235Nov 05 04:31 PM
ROTHBLATT MARTINE AChairman & CEONov 04Sale200.003,083616,600130Nov 05 04:33 PM
MAHON PAUL AEVP & General CounselNov 04Sale201.196,0001,207,15336,369Nov 04 04:31 PM
BENKOWITZ MICHAELPresident and COONov 02Option Exercise53.834,000215,3206,235Nov 03 04:37 PM
BENKOWITZ MICHAELPresident and COOOct 28Option Exercise53.834,000215,3206,235Oct 29 04:31 PM
BENKOWITZ MICHAELPresident and COOOct 26Option Exercise53.834,000215,3206,235Oct 27 04:32 PM
BENKOWITZ MICHAELPresident and COOOct 21Option Exercise53.834,000215,3206,235Oct 22 04:30 PM
MAHON PAUL AEVP & General CounselOct 21Option Exercise111.006,000666,00042,369Oct 21 04:30 PM
MAHON PAUL AEVP & General CounselOct 21Sale190.186,0001,141,08236,369Oct 21 04:30 PM
BENKOWITZ MICHAELPresident and COOOct 07Option Exercise53.834,000215,3206,235Oct 08 05:08 PM
MAHON PAUL AEVP & General CounselOct 07Option Exercise111.006,000666,00042,369Oct 07 04:31 PM
MAHON PAUL AEVP & General CounselOct 07Sale190.526,0001,143,14436,369Oct 07 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 23Option Exercise53.834,000215,3206,235Sep 24 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 21Option Exercise53.834,000215,3206,235Sep 22 04:37 PM
BENKOWITZ MICHAELPresident and COOSep 16Option Exercise53.834,000215,3206,235Sep 17 04:39 PM
MAHON PAUL AEVP & General CounselSep 16Option Exercise111.006,000666,00042,369Sep 16 04:31 PM
MAHON PAUL AEVP & General CounselSep 16Sale204.086,0001,224,46736,369Sep 16 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 14Option Exercise53.834,000215,3206,235Sep 15 04:33 PM
BENKOWITZ MICHAELPresident and COOSep 09Option Exercise53.834,000215,3206,235Sep 10 05:39 PM
BENKOWITZ MICHAELPresident and COOSep 07Option Exercise53.834,000215,3206,235Sep 08 06:19 PM
BENKOWITZ MICHAELPresident and COOSep 02Option Exercise53.834,000215,3206,235Sep 02 05:24 PM
MAHON PAUL AEVP & General CounselSep 02Option Exercise111.006,000666,00042,369Sep 02 05:25 PM
MAHON PAUL AEVP & General CounselSep 02Sale210.946,0001,265,65036,369Sep 02 05:25 PM
BENKOWITZ MICHAELPresident and COOAug 31Option Exercise53.834,000215,3206,235Sep 01 04:31 PM
BENKOWITZ MICHAELPresident and COOAug 26Option Exercise53.834,000215,3206,235Aug 27 04:32 PM
BENKOWITZ MICHAELPresident and COOAug 24Option Exercise53.834,000215,3206,235Aug 24 06:27 PM
MAHON PAUL AEVP & General CounselAug 23Option Exercise111.006,000666,00042,369Aug 24 04:33 PM
MAHON PAUL AEVP & General CounselAug 23Sale205.826,0001,234,90136,369Aug 24 04:33 PM